Skip to main content

Table 1 Selected clinical trials using PD-1 disrupted CAR T cells against solid tumors (from clinicalTrials.gov)

From: Hurdles to breakthrough in CAR T cell therapy of solid tumors

NCT number Title of study Types of tumor Interventions Phase Status
NCT04768608 PD1 integrated anti-PSMA CAR T in treating patients with castrate-resistant prostate cancer Castrate-Resistant Prostate Cancer PD1-PSMA-CART cells Phase 1 Not yet recruiting
NCT03030001 PD-1 antibody expressing CAR T cells for mesothelin positive advanced malignancies Solid Tumor, Adult PD-1 antibody expressing mesothelin-specific CAR-T cells Phase 1 Unknown
   Advanced Cancer   Phase 2  
NCT03179007 CTLA-4 and PD-1 antibodies expressing MUC1-CAR-T cells for MUC1 positive advanced solid tumor Advanced Solid Tumor Anti-CTLA-4/PD-1 expressing MUC1-CAR-T Phase 1 Unknown
     Phase 2  
NCT03615313 PD-1 antibody expressing mesoCAR-T cells for mesothelin positive advanced solid tumor Advanced Solid Tumor PD-1 antibody expressing mesoCAR-T cells Phase 1 Unknown
     Phase 2  
NCT04489862 αPD1-MSLN-CAR T cells for the treatment of MSLN-positive advanced solid tumors Non-small-cell Lung Cancer αPD1-MSLN-CAR T cells Early Phase 1 Recruiting
   Mesothelioma    
NCT03726515 CART-EGFRvIII + Pembrolizumab in GBM Glioblastoma CART-EGFRvIII T cells + Pembrolizumab Phase 1 Completed
NCT03747965 Study of PD-1 gene-knocked out mesothelin-directed CAR-T cells with the conditioning of PC in mesothelin positive multiple solid tumors Solid Tumor, Adult Mesothelin-directed CAR-T cells Phase 1 Unknown
NCT03545815 Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors Solid Tumor, Adult anti-mesothelin CAR-T cells Phase 1 Recruiting
  1. Programmed cell death protein 1(PD1), Prostate-specific membrane antigen (PSMA), Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Mucin 1 (MUC1), Mesothelin (MSLN), Epidermal growth factor receptor variant III (EGFRvIII), Glioblastoma (GBM), Paclitaxel and cyclophosphamide (PC), Clustered regularly interspaced short palindromic repeats (CRISPR), CRISPR-associated protein 9 (Cas9), T-cell receptor (TCR)